NIPH Clinical Trials Search

JAPANESE
国立保健医療科学院
JRCT ID: jRCTs051190076

Registered date:29/11/2019

Neo-adjuvant combination chemotherapy of Tranilast in esophageal carcinoma

Basic Information

Recruitment status Recruiting
Health condition(s) or Problem(s) studiedadvanced esophageal squamous cell carcinoma
Date of first enrollment14/11/2019
Target sample size59
Countries of recruitment
Study typeInterventional
Intervention(s)The additional use of tranilast to conventional neoadjuvant chemotherapy (5-FU/CDDP) for advanced esophageal squamous cell carcinoma patients

Outcome(s)

Primary OutcomePathological therapeutic effect
Secondary Outcomeclinical safety, therapeutic response diagnosed by imaging examination, down staging, ontological outcomes,

Key inclusion & exclusion criteria

Age minimum>= 20age old
Age maximum<= 74age old
GenderBoth
Include criteria1) Pathologically proven esophageal squamous cell carcinoma 2) Clinically diagnosed Stage II or Stage III esophageal squamous cell carcinoma patients in Japanese Classification of Esophageal Cancer, 11th edition 3) A case who was judged to be able to undergo radical esopagctomy under the general anesthesia 4) Age between 20 and 74 years old 5) A cases with ECOG Performance status 0,1 or 2 6) an essentially normal clinical laboratory profile (serum creatinine: <=1.2 mg /dl; (creatinine clearance or CCr) >=60 ml/minute; total serum bilirubin: <=1.2 mg /dl; aspartate aminotransaminase or AST and alanine aminotransaminase or ALT: no higher than twice upper limit of normal value defined in our institution; white blood cell count: >=4,000 /mm3; haemoglobin: >=10g /dl; platelet count: >=100,000 /mm3 7) A case that can take medicine. 8) Oral and written informed consent obtained before registration
Exclude criteria1) A history of chemotherapy or radiotherapy 1 year before treatment begins 2) Tumor with active bleeding 3) A case with histories of acute myocardial infarction, severe angina, congested heart failure, cerebrovascular disease, or pulmonary thrombosis within 6 months before registration 4) A case with uncontrolled asthma 5) A history of laparotomy or trachotomy within 4 weeks before treatment begins 6) A case with allergy of tranilast 7) A female with a possibility of pregnancy, breastfeeding to infant, and desire to bear children 8) A case judged as inappropriate for the present clinical trial by the chief researcher 9) A case that take some similar drugs to tranilast 10) A case with transfusion within 14 days before registration 11) Current medication of warfarin

Related Information

Contact

Public contact
Name Michihiro Kudou
Address 465 Kajii-cho, Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto, JAPAN. Kyoto Japan 602-8566
Telephone +81-752515527
E-mail posit@koto.kpu-m.ac.jp
Affiliation University Hospital Kyoto prefectural University of Medicine
Scientific contact
Name Atsushi Shiozaki
Address 465 Kajii-cho, Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto, JAPAN. Kyoto Japan 602-8566
Telephone +81-752515527
E-mail shiozaki@koto.kpu-m.ac.jp
Affiliation University Hospital Kyoto prefectural University of Medicine